冠通方对冠状动脉裸金属支架植入术后再狭窄和IL8水平的影响
-
摘要: 目的 观察加用冠通方预防经皮冠状动脉腔内成形术(PTCA)及裸金属支架植入术后再狭窄和对IL8水平的影响。方法 将120例冠心病介入治疗患者,随机分成冠通方(由三七、丹参、地龙、瓜蒌、生晒参、绞股蓝、陈皮、麦冬组成)加西药(口服肠溶阿司匹林、氯吡格雷、阿托伐他汀、倍他洛克等)治疗组(简称治疗组)60例;西药(口服肠溶阿司匹林、氯吡格雷、阿托伐他汀、倍他洛克等)治疗组(简称对照组)60例。治疗6个月后对患者术后心绞痛复发、IL8水平及冠状动脉造影等进行随访观察。结果 治疗组心绞痛复发率显著低于对照组(P<0.01);2组患者共有95例复查冠状动脉造影,其中治疗组48例中,再狭窄发生率9.84%;对照组47例中,再狭窄发生率23.73%,2组比较再狭窄发生率差异有显著性意义(P<0.05);2组IL8水平比较差异有显著性意义(P<0.01)。结论 冠通方能降低裸金属支架植入术后IL8的水平,可预防冠状动脉再狭窄。
-
[1] 齐晓勇,冠心病介入治疗前后白细胞介素-8变化的意义,河北医科大学学报,2002(02). [2] Ockene IS;Matthews CE;Rifai N,Variability and cassification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults,Clinical Chemistry,2001(03). [3] 胜国印;贾国良;陈十良,冠心病患者血浆IL-8的变化及临床意义,临床心血管病杂志,1995(11). [4] Gaspardone A;Crea F;Versaci F,Predictive value of creactive protein after successful coronary-artery stenting in patients with stable angina,American Journal of Cardiology,1998(02). [5] 余佳霖;叶天星;陆德源,现代医学免疫学,上海:上海医科大学出版社,1998. [6] Stringer KA,TIMI grade flow,mortality,and the GVSTO-Ⅲ trial,Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy,1998(04). [7] 陈灏珠,实用内科学,北京:人民卫生出版社,2005. [8] 陈灏珠,实用内科学,北京:人民卫生出版社,2005. [9] Stringer KA,TIMI grade flow,mortality,and the GVSTO-Ⅲ trial,Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy,1998(04). [10] 余佳霖;叶天星;陆德源,现代医学免疫学,上海:上海医科大学出版社,1998. [11] GASPARDONE A;CREA F;VERSACI F,Predictive value of C2reactive protein after successful coronary artery stenting in patients with stable angina,American Journal of Cardiology ,1998, 82(04). [12] 胜国印;贾国良;陈十良,冠心病患者血浆IL-8的变化及临床意义,临床心血管病杂志,1995(11). [13] Ockene IS;Matthews CE;Rifai N Variability and cassification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults [J] 2001(03) [14] 齐晓勇,冠心病介入治疗前后白细胞介素-8变化的意义,河北医科大学学报,2002(02).
点击查看大图
计量
- 文章访问数: 888
- HTML全文浏览量: 1
- PDF下载量: 0
- 被引次数: 0